News | April 12, 2026
EMA gives green light to warmer & simpler delivery rules for Wegovy injection
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
The study is a global, randomized, double-blind, placebo-controlled trial testing GLM101 for phosphomannomutase 2 congenital disorder of glycosylation
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Move aligns global biologics identity under the Biocon Biologics brand
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Its a major breakthrough for women’s ovarian cancer care in Europe
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
Subscribe To Our Newsletter & Stay Updated
